Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …

Immunotherapy has achieved great success recently and opened a new avenue for anti-
tumor treatment. Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) …

Despite advances in cancer treatment, immune checkpoint blockade (ICB) only achieves
complete response in some patients, illustrating the need to identify resistance mechanisms …

The cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) plays a critical role in antiviral
immunity and autoimmunity. The activity and stability of cGAS are fine-tuned by post …

As the ubiquitin–proteasome system (UPS) regulates almost every biological process, the
dysregulation or aberrant expression of the UPS components causes many pathological …

Cancer immunotherapy using anti‐programmed death‐ligand 1 (PD‐L1) antibodies has
been used in various clinical applications and achieved certain results. However, such …

The immune checkpoint molecules programmed cell death receptor 1 (PD-1) and
programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor …

Immune cells can protect against tumor progression by killing cancer cells, while aberrant
expression of the immune checkpoint protein PD‐L1 (programmed death ligand 1) in cancer …

Programmed death-ligand 1 (PD-L1), a critical immune checkpoint ligand, is a
transmembrane protein synthesized in the endoplasmic reticulum of tumor cells and …